Literature DB >> 21878842

Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model.

Paula Schaiquevich1, Emiliano Buitrago, Alejandro Ceciliano, Adriana C Fandino, Marcelo Asprea, Sergio Sierre, David H Abramson, Guillermo F Bramuglia, Guillermo L Chantada.   

Abstract

PURPOSE: To characterize the vitreous and plasma pharmacokinetics of topotecan after ophthalmic artery infusion (OAI) subsequent to superselective artery catheterization and to compare it with periocular injection (POI).
METHODS: The ophthalmic artery of 4 pigs was catheterized and 1 mg of topotecan infused over a period of 30 minutes. The contralateral eye was subsequently used for administering topotecan by POI. Serial vitreous specimens were obtained by microdialysis and plasma samples collected and assayed for total and lactone topotecan.
RESULTS: Maximum total topotecan concentration in the vitreous (median, range) was significantly higher after OAI compared with POI (131.8 ng/mL [112.9-138.7] vs. 13.6 ng/mL [5.5-15.3], respectively; P < 0.005). Median vitreous exposure calculated as area under the curve for total topotecan attained after OAI was significantly higher than after POI (299.8 ng·hour/mL [247.6-347.2] and 48.9 ng·hour/mL [11.8-63.4], respectively; P < 0.05). The vitreous to plasma exposure ratio was 29 after OAI and 3.4 after POI. Systemic exposure for total topotecan was low after both modalities of administration, with a trend to be lower after OAI compared with POI (10.6 ng·hour/mL [6.8-13.4] vs. 18.7 ng·hour/mL [6.3-21.7]; P = 0.54).
CONCLUSION: Superselective OAI resulted in significantly higher vitreous concentrations and exposure and a trend toward lower systemic exposure than POI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21878842     DOI: 10.1097/IAE.0b013e31821e9f8a

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

Authors:  Jena J Steinle; Qiuhua Zhang; Karin Emmons Thompson; Jordan Toutounchian; C Ryan Yates; Carl Soderland; Fan Wang; Clinton F Stewart; Barrett G Haik; J Scott Williams; J Scott Jackson; Timothy D Mandrell; Dianna Johnson; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-30       Impact factor: 4.799

2.  Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma.

Authors:  Jasmine H Francis; Christopher A Barker; Suzanne L Wolden; Beryl McCormick; Kira Segal; Gil Cohen; Y Pierre Gobin; Brian P Marr; Scott E Brodie; Ira J Dunkel; David H Abramson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-14       Impact factor: 7.038

Review 3.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 4.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

Review 5.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08

6.  Twenty-Year Collaboration Between North American and South American Retinoblastoma Programs.

Authors:  Guillermo L Chantada; Ira J Dunkel; Paula S Schaiquevich; Edith L Grynszpancholc; Jasmine Francis; Alejandro Ceciliano; Pedro A Zubizarreta; Adriana C Fandiño; David H Abramson
Journal:  J Glob Oncol       Date:  2016-03-30

7.  A decision process for drug discovery in retinoblastoma.

Authors:  María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  Invest New Drugs       Date:  2020-11-16       Impact factor: 3.850

8.  Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.

Authors:  Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

9.  Intravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.

Authors:  Mohammad Ali Gholipour; Mozhgan Rezaei Kanavi; Hamid Ahmadieh; Seyed Javid Aldavood; Ramin Nourinia; Seyed Bagher Hosseini; Narsis Daftarian; Ebrahim Mohammad Nashtaei; Adib Tousi; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2015 Jul-Sep

10.  Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery.

Authors:  Paula Taich; Flavio Requejo; Marcelo Asprea; Mariana Sgroi; Pierre Gobin; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.